| Recruiting | Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic NCT07039422 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune NCT07083739 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia NCT06900920 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Recruiting | Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. NCT06531018 | Renata PLC | Phase 1 / Phase 2 |
| Completed | Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP) NCT06665308 | Sanofi | — |
| Recruiting | Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP NCT06686927 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Active Not Recruiting | Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) NCT06594146 | Keymed Biosciences Co.Ltd | Phase 2 |
| Not Yet Recruiting | Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010 NCT06466824 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP NCT06658834 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune NCT06291415 | Hutchmed | Phase 1 |
| Completed | The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects NCT06148389 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) NCT06107582 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Completed | Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study NCT06071520 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Active Not Recruiting | A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thromb NCT05653219 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopen NCT05325593 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 3 |
| Completed | Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) NCT05422365 | Biopharma Plasma LLC | Phase 3 |
| Unknown | Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients NCT05311930 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Unknown | Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purp NCT05371743 | Sohag University | — |
| Not Yet Recruiting | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With I NCT05333861 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Unknown | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia NCT05232149 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Recruiting | Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia NCT05070845 | Pfizer | Phase 2 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With P NCT04812925 | argenx | Phase 3 |
| Unknown | Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP) NCT04949009 | Shandong University | — |
| Terminated | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participan NCT04596995 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary I NCT04687072 | argenx | Phase 3 |
| Completed | A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia NCT04278924 | Takeda | Phase 2 |
| Terminated | A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With P NCT04224688 | UCB Biopharma SRL | Phase 3 |
| Completed | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thro NCT04225156 | argenx | Phase 3 |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With NCT04200456 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopen NCT04188379 | argenx | Phase 3 |
| Unknown | Effect of DNMT SNPs on DNA Methylation in Primary ITP NCT04100876 | Assiut University | — |
| Completed | Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia NCT05621330 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) NCT03771378 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Completed | Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine NCT05551624 | Hospital Civil de Guadalajara | EARLY_Phase 1 |
| Terminated | A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 NCT03275740 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP NCT03102593 | argenx | Phase 2 |
| Completed | Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regim NCT01727232 | Henri Mondor University Hospital | — |
| Available | Managed Access Programs for VAY736, Ianalumab NCT07244289 | Novartis Pharmaceuticals | — |